We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$62.4M
Cap. Flow
-$7.23M
Cap. Flow %
-2.13%
Top 10 Hldgs %
54.94%
Holding
37
New
8
Increased
4
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
SGHT icon
Sight Sciences
SGHT
+$11.3M
2
RPID icon
Rapid Micro Biosystems
RPID
+$9.05M
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$9.02M
4
CELL
PhenomeX Inc. Common Stock
CELL
+$7.68M
5
MGNX icon
MacroGenics
MGNX
+$6.07M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$17.3M
2
EPIX
ESSA Pharma
EPIX
+$10.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$8.02M
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$5.74M
5
APLS
Apellis Pharmaceuticals
APLS
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 86.86%
2 Miscellaneous 10.3%
3 Materials 1.42%
4 Financials 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.3B
$29.9M 8.78%
268,000
+50,000
+23% +$5.73M
XNTK icon
2
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.01B
$25.1M 7.39%
200,000
– –
RGEN icon
3
Repligen
RGEN
$9.46B
$20.2M 5.95%
70,000
-12,500
-15% -$3.21M
ARVN icon
4
Arvinas
ARVN
$614M
$17.3M 5.07%
210,000
-30,000
-13% -$2.65M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.8M 4.94%
95,000
– –
NUVB icon
6
Nuvation Bio
NUVB
$2.39B
$16.5M 4.85%
1,660,947
-47,144
-3% -$427K
FATE icon
7
Fate Therapeutics
FATE
$297M
$16M 4.71%
270,000
– –
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.4M 4.52%
343,990
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.6B
$14.9M 4.38%
904,978
+45,068
+5% +$661K
GOSS icon
10
Gossamer Bio
GOSS
$85.7M
$14.8M 4.34%
1,175,000
– –
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.85B
$14.7M 4.32%
575,940
+65,533
+13% +$1.53M
COGT icon
12
Cogent Biosciences
COGT
$6.03B
$13.6M 4.01%
1,622,591
– –
IOVA icon
13
Iovance Biotherapeutics
IOVA
$3.98B
$10M 2.95%
406,986
– –
SLGC
14
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$9.91M 2.91%
+800,000
New +$9.02M
APLS
15
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$9.89M 2.91%
300,000
– –
NAUT icon
16
Nautilus Biotechnolgy
NAUT
$115M
$9.21M 2.71%
1,500,000
– –
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$8.88M 2.61%
185,000
– –
NTLA icon
18
Intellia Therapeutics
NTLA
$1.79B
$8.72M 2.56%
65,000
-28,127
-30% -$4.26M
MDVL
19
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$8.53M 2.51%
58,416
– –
RPID icon
20
Rapid Micro Biosystems
RPID
$65.7M
$8.09M 2.38%
+437,960
New +$9.05M
SGHT icon
21
Sight Sciences
SGHT
$460M
$7.77M 2.28%
+342,304
New +$11.3M
MGNX icon
22
MacroGenics
MGNX
$280M
$7.64M 2.25%
365,000
+252,161
+223% +$6.07M
NVTA
23
DELISTED
Invitae Corporation
NVTA
$5.68M 1.67%
199,900
-100,100
-33% -$2.93M
CYT
24
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$5.61M 1.65%
319,538
-307,305
-49% -$5.74M
AMRS
25
DELISTED
Amyris Inc.
AMRS
$4.84M 1.42%
+352,445
New +$5.05M
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q3 2021 Portfolio in Review

As of Q3 2021, Ally Bridge Group held 37 positions worth $340M, down 16% from $403M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Ally Bridge Group's Q3 2021 filing shows 8 new, 4 increased, 7 reduced and 6 closed positions. Its largest new stake was Sight Sciences: 342,304 shares worth $7.77M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Materials.

  • Ally Bridge Group's largest Q3 2021 buy was Sight Sciences: 342,304 shares worth $7.77M.
  • Ally Bridge Group added most to MacroGenics in Q3 2021, an estimated $6.07M increase.
  • Ally Bridge Group's biggest Q3 2021 reduction was Cyteir Therapeutics, Inc. Common Stock, cutting an estimated $5.74M.
  • Ally Bridge Group fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Ally Bridge Group's ten largest holdings make up 55% of its $340M portfolio in Q3 2021.
  • Ally Bridge Group opened 8 new positions and closed 6 in Q3 2021.
  • Ally Bridge Group's portfolio value fell 16% quarter-over-quarter to $340M.

Based on Ally Bridge Group's 13F filing for Q3 2021, filed 15 Nov 2021.